Industry partners-sharing the load

Article

The author describes peoples' and organizations' service to the industry.

Over the past 30 years, my position has given me the privilege of really getting to know our industry partners. By and large, the companies that supply us with the goods and services that make patient care easier have truly invested in our profession.

My personal hall of fame includes Dave Hansen, OD, from AMO; Rick Weisbarth, OD, with Ciba (now Alcon); Mike Pier, OD, of B + L; Rod Tahran, OD, from Essilor; Henry Sand with Luxottica; and Dawn Holsted, OD, of TLC. Probably the true pioneer in this group was Stan Yamane, OD, of Vistakon, who really understood what professional relations was all about, and his successor, Pat Cummings, OD.

Congratulations to all of these individuals for their help and support to our great profession.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.